Body Weight Changes in People with HIV Starting Dolutegravir Versus Efavirenz-based Regimens in a Large Cohort in Rural Tanzania

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2024 Dec 5

PMID 39632712

Authors

Maja Weisser

Herry Mapesi

Fiona Vanobberghen

James Okuma

Anna Eichenberger

Herieth Ismael Wilson

Daniel Henry Paris

Aneth Vedastus Kalinjuma

Ezekiel Luoga

Lulu Wilson

Tracy Renee Glass

Fabian Christoph Franzeck

Affiliations

Soon will be listed here.

Abstract

Objectives: To analyze weight changes associated with dolutegravir- versus efavirenz-based antiretroviral therapy (ART) in people with HIV (PWH) in rural Tanzania, where undernutrition is prevalent.

Design: Longitudinal, observational study of the prospective Kilombero and Ulanga Antiretroviral Cohort (KIULARCO).

Methods: We included adult, ART-naïve, nonpregnant PWH initiating efavirenz-based ART 12/2016-02/2019 or dolutegravir-based ART 03/2019-12/2022. We used multivariable linear mixed-effects models to assess adjusted weight changes during 18 months after ART start and Cox regression models to assess factors associated with incident obesity, weight gain ≥10% and hypertension.

Results: Of 1205 PWH at ART start [median age 40 years (interquartile range (IQR) 32-48); 719 (59.7%) females], 166 (13.8%) individuals were underweight and 317 (26.3%) overweight/obese; 621 (51.5%) initiated efavirenz-based and 584 (48.5%) dolutegravir-based ART. After 18 months, estimated weight gain was 5.1 kg [95% confidence interval (CI) 4.7-5.5] in the dolutegravir versus 4.0 kg (95% CI 3.7-4.4) in the efavirenz group. The weight gain difference between treatment groups was high in men (1.7 kg (95% CI 0.8-2.6; P < 0.001)), in those aged 30-49 years (1.5 kg (0.8-2.1); P < 0.001) and those with CD4 + cell count ≥500/ul (2.5 kg (1.4-3.7), P < 0.001)). Cumulative obesity incidence at 18 months was 10.9% (95% CI 8.3-14.0) in the dolutegravir and 5.1% (95% CI 3.6-7.1) in the efavirenz group. Associated factors were dolutegravir and a pre-ART body mass index (BMI) of 25-29 kg/m 2 . Dolutegravir and age, but not weight gain were associated with incident of hypertension.

Conclusions: Dolutegravir-based ART was associated with more weight gain, higher obesity and hypertension - especially in those with a higher pre-ART BMI compared to efavirenz-based regimens.

References

Griesel R, Kawuma A, Wasmann R, Sokhela S, Akpomiemie G, Francois Venter W . Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2021; 88(3):883-893. PMC: 7612404. DOI: 10.1111/bcp.15177. View

Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S . Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9):816-826. DOI: 10.1056/NEJMoa1904340. View

Brennan A, Nattey C, Kileel E, Rosen S, Maskew M, Stokes A . Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa. EClinicalMedicine. 2023; 57:101836. PMC: 9932660. DOI: 10.1016/j.eclinm.2023.101836. View

Vanobberghen F, Letang E, Gamell A, Mnzava D, Faini D, Luwanda L . A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS One. 2017; 12(7):e0180983. PMC: 5515476. DOI: 10.1371/journal.pone.0180983. View

Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S . Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020; 7(10):e677-e687. DOI: 10.1016/S2352-3018(20)30238-1. View

McComsey G, Moser C, Currier J, Ribaudo H, Paczuski P, Dube M . Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis. 2016; 62(7):853-62. PMC: 4787610. DOI: 10.1093/cid/ciw017. View

Schouten J, Wit F, Stolte I, Kootstra N, Van Der Valk M, Geerlings S . Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014; 59(12):1787-97. DOI: 10.1093/cid/ciu701. View

Sinxadi P, Leger P, McIlleron H, Smith P, Dave J, Levitt N . Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. 2015; 80(1):146-56. PMC: 4500334. DOI: 10.1111/bcp.12590. View

Rizzardo S, Lanzafame M, Lattuada E, Luise D, Vincenzi M, Tacconelli E . Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. AIDS. 2019; 33(10):1673-1674. DOI: 10.1097/QAD.0000000000002245. View

10.

Haubrich R, Riddler S, DiRienzo A, Komarow L, Powderly W, Klingman K . Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009; 23(9):1109-18. PMC: 2739977. DOI: 10.1097/QAD.0b013e32832b4377. View

11.

Letang E, Kalinjuma A, Glass T, Gamell A, Mapesi H, Sikalengo G . Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. Swiss Med Wkly. 2017; 147:w14485. DOI: 10.4414/smw.2017.14485. View

12.

Herrin M, Tate J, Akgun K, Butt A, Crothers K, Freiberg M . Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr. 2016; 73(2):228-36. PMC: 5023454. DOI: 10.1097/QAI.0000000000001071. View

13.

Esber A, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J . Weight gain during the dolutegravir transition in the African Cohort Study. J Int AIDS Soc. 2022; 25(4):e25899. PMC: 9008168. DOI: 10.1002/jia2.25899. View

14.

Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S . Dolutegravir and weight gain: an unexpected bothering side effect?. AIDS. 2017; 31(10):1499-1500. DOI: 10.1097/QAD.0000000000001495. View

15.

Achhra A, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S . Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2015; 17(4):255-68. DOI: 10.1111/hiv.12294. View

16.

Kerchberger A, Sheth A, Angert C, Mehta C, Summers N, Ofotokun I . Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2019; 71(3):593-600. PMC: 7384314. DOI: 10.1093/cid/ciz853. View

17.

Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M . CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2020; 73(11):e3902-e3909. PMC: 8653639. DOI: 10.1093/cid/ciaa1073. View

18.

Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F . The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?. AIDS. 2018; 32(12):1551-1561. DOI: 10.1097/QAD.0000000000001845. View

19.

Bourgi K, Rebeiro P, Turner M, Castilho J, Hulgan T, Raffanti S . Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2019; 70(7):1267-1274. PMC: 8205610. DOI: 10.1093/cid/ciz407. View

20.

Drozd D, Kitahata M, Althoff K, Zhang J, Gange S, Napravnik S . Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr. 2017; 75(5):568-576. PMC: 5522001. DOI: 10.1097/QAI.0000000000001450. View